INCANNEX HEALTHCARE INC.

Press Releases Incannex Healthcare Inc.

Equities

IXHL

US45333F1093

Market Closed - Nasdaq Other stock markets 21:30:01 24/05/2024 BST			5-day change	1st Jan Change
2.78 ^USD	+2.96%		+8.81%	-40.09%

05-07	Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder	CI
03-05	Incannex Healthcare Inc. Announces CFO Changes	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder	05-07	AQ
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)	05-01	NE
Incannex Healthcare Inc. Quarterly Update, Q1 2024	04-16	AQ
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	02-28	AQ
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation	02-16	AQ
Clarion Clinics Open for Psychedelic-Assisted Treatments	02-01	AQ
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	01-24	AQ
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences	01-18	AQ
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	01-17	AQ
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia	12-21	AQ
Incannex Healthcare : Change in Certifying Accountants - Form 8-K	12-15	PU
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	12-06	AQ
Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors	17/08/22	GL
Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion	10/05/22	PR
Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M	28/04/22	PR
Incannex to Acquire APIRx Pharmaceuticals USA, LLC	24/03/22	PR
Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies	10/03/22	PR
Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics	03/03/22	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer